Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $20.1 million versus the consensus estimate of $12.36 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.